The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis

Multidrug-resistant (MDR) strains of Mycobacterium tuberculosis have emerged worldwide. In many countries and regions, these resistant strains constitute a serious threat to the efficacy of tuberculosis control programs. An important element in gaining control of this epidemic is developing an understanding of the molecular basis of resistance to the most important antituberculosis drugs: isoniazid, rifampin, and pyrazinamide. On the basis of this information, more exacting laboratory testing, and ultimately more appropriate and timely treatment regimens, can be developed.

• Publication year

  2001

• Venue

  Respiratory Research

• Publication date

  2001-04-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/rr54PMID 11686881PMCID 2002067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.

  2015cited by this paper
• Macrolide Resistance Conferred by Base Substitutions in 23S rRNA

  2001cited by this paper
• Analysis for a Limited Number of Gene Codons Can Predict Drug Resistance of Mycobacterium tuberculosis in a High-Incidence Community

  2001cited by this paper
• Inactivation of the inhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis of Mycobacterium smegmatis

  2000cited by this paper
• Genotypic Analysis of Mycobacterium tuberculosis in Two Distinct Populations Using Molecular Beacons: Implications for Rapid Susceptibility Testing

  2000cited by this paper
• Molecular genetics of mycobacteria.

  2000cited by this paper
• Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis

  2000cited by this paper
• A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

  2000cited by this paper
• Access to newer laboratory procedures: a call for action.

  2000cited by this paper
• Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis

  2000cited by this paper
• Standardization of antituberculosis drug resistance surveillance in Europe. Recommendations of a World Health Organization (WHO) and International Union Against Tuberculosis and Lung Disease (IUATLD) Working Group.

  2000cited by this paper
• Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis.

  2000cited by this paper
• Mutations in the Beginning of the rpoBGene Can Induce Resistance to Rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis

  2000cited by this paper
• Contribution of kasA Analysis to Detection of Isoniazid-Resistant Mycobacterium tuberculosisin Singapore

  1999cited by this paper
• Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.

  1999cited by this paper
• Role of Acid pH and Deficient Efflux of Pyrazinoic Acid in Unique Susceptibility of Mycobacterium tuberculosis to Pyrazinamide

  1999cited by this paper
• Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.

  1998cited by this paper
• Antisense RNA to ahpC, an oxidative stress defence gene involved in isoniazid resistance, indicates that AhpC of Mycobacterium bovis has virulence properties.

  1998cited by this paper
• Guidelines for surveillance of drug resistance in tuberculosis. WHO Geneva/IUATLD Paris. International Union Against Tuberculosis and Lung Disease.

  1998cited by this paper
• Erratum: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

  1998cited by this paper
• Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

  1998influential reference
• Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

  1998cited by this paper
• A Ser315Thr Substitution in KatG Is Predominant in Genetically Heterogeneous Multidrug-Resistant Mycobacterium tuberculosis Isolates Originating from the St. Petersburg Area in Russia

  1998cited by this paper
• Drug resistance in tuberculosis.

  1997cited by this paper
• Mycobacterium tuberculosis cell envelope.

  1996cited by this paper
• Compensatory ahpC Gene Expression in Isoniazid-Resistant Mycobacterium tuberculosis

  1996cited by this paper
• Site‐directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase–peroxidase activities and isoniazid resistance

  1996cited by this paper
• Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus

  1996cited by this paper
• Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

  1996cited by this paper
• Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan

  1996cited by this paper
• Distribution and characterization of beta-lactamases of mycobacteria and related organisms.

  1995cited by this paper
• Distribution and characterization of β-lactamases of mycobacteria and related organisms

  1995cited by this paper
• Mechanistic Studies of the Oxidation of Isoniazid by the Catalase Peroxidase from Mycobacterium tuberculosis

  1994cited by this paper
• Mycobacterial cell wall: structure and role in natural resistance to antibiotics.

  1994cited by this paper
• Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study

  1994cited by this paper
• Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

  1993cited by this paper
• The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis

  1992cited by this paper
• The Garrod Lecture. Understanding the chemotherapy of tuberculosis--current problems.

  1992cited by this paper
• Understanding the chemotherapy of tuberculosis—current problems

  1992cited by this paper
• Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system.

  1990cited by this paper
• [International Union against Tuberculosis and Lung Disease].

  1989cited by this paper
• The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.

  1978cited by this paper
• Pyrazinamide susceptibility and amidase activity of tubercle bacilli.

  1967cited by this paper
• Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report.

  1954cited by this paper

• Genetic Analysis of Molecular Mechanisms of Drug Resistance in Mycobacterium tuberculosis Against Four Major First-Line Anti-Tuberculosis Drugs (Isoniazid, Rifampin, Ethambutol, and Pyrazinamide)

  2025cites this paper
• Computational Design of Multitargeted Ligands to Counter Drug Resistance of Mycobacterium Tuberculosis

  2025cites this paper
• Role of Different Isoniazid Analogs as Antitubercular Agents

  2025cites this paper
• Efflux pumps positively contribute to rifampin resistance in rpoB mutant Mycobacterium tuberculosis

  2025cites this paper
• Prevalence and Clinical Implications of Pyrazinamide Resistance in Newly Diagnosed TB Patients in Uganda

  2025cites this paper
• Diagnostic Performance of Smear Microscopy and Xpert MTB/RIF Versus MGIT Culture in Republic of Congo

  2025cites this paper
• Direct detection from sputum for drug-resistant Mycobacterium tuberculosis using a CRISPR-Cas14a-based approach

  2025cites this paper
• Recent Biochemical Advances in Antitubercular Drugs: Challenges and Future.

  2024cites this paper
• Structures of the essential efflux pump EfpA from Mycobacterium tuberculosis reveal the mechanisms of substrate transport and small-molecule inhibition

  2024cites this paper
• Structures of the Mycobacterium tuberculosis efflux pump EfpA reveal the mechanisms of transport and inhibition

  2024influential citation
• Molecular Characterization of Multi Drug Resistant Mycobacterium tuberculosis Isolated from the Patients in the Hospital of Azad Jammu and Kashmir

  2024cites this paper
• The challenges in combating multidrug-resistant Mycobacterium tuberculosis

  2024cites this paper
• Identification of a 2‐Aminobenzimidazole Scaffold that Potentiates Gram‐Positive Selective Antibiotics Against Gram‐Negative Bacteria

  2024cites this paper
• Mutational analysis of the rpoB gene of Mycobacterium Tuberculosis Strains

  2024cites this paper
• Isoniazid Analogs and Their Biological Activities as Antitubercular Agents (A Review)

  2024cites this paper
• Bifidobacterium adolescentis is resistant to pyrazinamide, isoniazid, and streptomycin

  2024cites this paper
• Activity against Mycobacterium tuberculosis of a new class of spirooxindolopyrrolidine embedded chromanone hybrid heterocycles

  2024cites this paper
• Confronting Tuberculosis: A Synthetic Quinoline-Isonicotinic Acid Hydrazide Hybrid Compound as a Potent Lead Molecule Against Mycobacterium tuberculosis.

  2024cites this paper
• Synergistic combination of antimicrobial peptide and isoniazid as inhalable dry powder formulation against multi-drug resistant tuberculosis.

  2024cites this paper
• Multi-drug resistant gene mutation analysis in Mycobacterium tuberculosis by molecular techniques

  2024cites this paper
• Complete genome annotation data of Mycobacteriophages Prann and LeoAvram: New members of the family Siphoviridae.

  2023cites this paper
• Determination of Isoniazid Gained Fluorescent with 9-Anthraldehyde by HPLC-FL Method in Dosage Forms

  2023cites this paper
• A Complex Case of Pulmonary Silico-Tuberculosis and Review of Literature

  2023cites this paper
• Clinico-microbiological profile and treatment outcomes in patients with isoniazid monoresistant tuberculosis in South India

  2023cites this paper
• Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing

  2023cites this paper
• An Overview of Various Rifampicin Analogs against Mycobacterium tuberculosis and their Drug Interactions.

  2023cites this paper
• Mapping Research Trends of Medications for Multidrug-Resistant Pulmonary Tuberculosis Based on the Co-Occurrence of Specific Semantic Types in the MeSH Tree: A Bibliometric and Visualization-Based Analysis of PubMed Literature (1966–2020)

  2023cites this paper
• Designing New Magic Bullets to Penetrate the Mycobacterial Shield: An Arduous Quest for Promising Therapeutic Candidates

  2023cites this paper
• Analysis of Discordance between Genotypic and Phenotypic Assays for Rifampicin-Resistant Mycobacterium tuberculosis Isolated from Healthcare Facilities in Mthatha

  2023cites this paper
• Computational insights into potential marine natural products as selective inhibitors of Mycobacterium tuberculosis InhA: A structure-based virtual screening study

  2023cites this paper
• A meta-analysis of the accuracy of Xpert MTB/RIF in diagnosing intestinal tuberculosis.

  2023cites this paper
• A pro-oxidant property of vitamin C to overcome the burden of latent Mycobacterium tuberculosis infection: A cross-talk review with Fenton reaction

  2023cites this paper
• Potential Use of Mycobacterium paragordonae for Antimycobacterial Drug Screening Systems

  2023cites this paper
• Study of structurally diverse currently used and recently developed antimycobacterial drugs.

  2023cites this paper
• Ultrasensitive Detection of Multidrug-Resistant Mycobacterium tuberculosis Using SuperSelective Primer-Based Real-Time PCR Assays

  2022cites this paper
• Effect of Local Use of Rifampicin on the Development of Surgical Site Infection after Lumbar Microdiscectomy.

  2022cites this paper
• Genome-wide analysis to detect multi-drug resistance genes in Mycobacterium tuberculosis strains SWLPK and MNPK resourced from Pakistan

  2022cites this paper
• Trends in the Incidence of Rifampicin Resistant Mycobacterium tuberculosis Infection in Northeastern Nigeria

  2022cites this paper
• Tools to Alleviate the Drug Resistance in Mycobacterium tuberculosis

  2022cites this paper
• Evaluation of three alternatives cost-effective culture media for Mycobacterium tuberculosis detection and drug susceptibility determination using the microscopic observation drug susceptibility (MODS) assay.

  2022cites this paper
• In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis

  2022cites this paper
• Marine Macrolides to Tackle Antimicrobial Resistance of Mycobacterium tuberculosis

  2022cites this paper
• Efficient and Greener Synthesis of Functionalized Isoniazid Azomethines from Aromatic Aldehydes and Isatins Using Citric Acid in Aqueous Ethanol

  2021cites this paper
• Socio Demographic Profile of Rifampicin Resistant Patient in Surat City

  2021cites this paper
• Accurate Identification of Closely Related Mycobacterium tuberculosis Complex Species by High Resolution Tandem Mass Spectrometry

  2021cites this paper
• Morphology, Anatomy and Secondary Metabolites Investigations of Premna odorata Blanco and Evaluation of Its Anti-Tuberculosis Activity Using In Vitro and In Silico Studies

  2021cites this paper
• Targeting Molecular and Cellular Mechanisms in Tuberculosis

  2021cites this paper
• The Mycobacterial Efflux Pump EfpA Can Induce High Drug Tolerance to Many Antituberculosis Drugs, Including Moxifloxacin, in Mycobacterium smegmatis

  2021cites this paper
• Interaction of host pattern recognition receptors (PRRs) with Mycobacterium tuberculosis and Ayurvedic management of tuberculosis: a systemic approach.

  2021cites this paper
• Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa

  2021cites this paper
• Characterisation of Mutations Associated with Rifampicin Resistance in Patients Attending a Tertiary Care Centre, Kerala

  2021cites this paper
• Impact of Bi Doping into Boron Nitride Nanosheets on Electronic and Optical Properties Using Theoretical Calculations and Experiments

  2021cites this paper
• Experimental Evolution of Magnetite Nanoparticle Resistance in Escherichia coli

  2021cites this paper
• Prevalence of isoniazid resistance in cases of rifampicin resistance detected on GeneXpert MTB/RIF assay.

  2021cites this paper
• Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages

  2021cites this paper
• Rifampicin Mono-Resistant Tuberculosis—A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control

  2021cites this paper
• Network approach to mutagenesis sheds insight on phage resistance in mycobacteria

  2021cites this paper
• Challenges in Drug Discovery against Tuberculosis

  2021cites this paper
• Rifampin-resistance-associated mutations in the rifampin-resistance-determining region of the rpoB gene of Mycobacterium tuberculosis clinical isolates in Shanghai, PR China.

  2021cites this paper
• Spatial relationships of intra-lesion heterogeneity in Mycobacterium tuberculosis microenvironment, replication status, and drug efficacy

  2021cites this paper
• WHO EMRO | Predictive factors of death in patients with tuberculosis: a nested case–control study

  2020cites this paper
• Regio- and diastereoselective synthesis of spiropyrroloquinoxaline grafted indole heterocyclic hybrids and evaluation of their anti-Mycobacterium tuberculosis activity

  2020cites this paper
• Mutations Associated with Rifampicin Resistance in Mycobacterium tuberculosis Isolates from Moroccan Patients: Systematic Review

  2020cites this paper
• Mutation Profile Assessment of rpoB, KatG and inhA Genes in Rifampicin and Isoniazid Resistant Mycobacterium tuberculosis in India

  2020cites this paper
• Mechanism of Drug Resistance in Mycobacterium Tuberculosis

  2020cites this paper
• Délais de Conversion des Frottis d’Expectoration Positifs chez les Patients Tuberculeux Pulmonaires Traités à Brazzaville

  2020cites this paper
• Prevalence of Antibiotic-Resistant Pulmonary Tuberculosis in Bangladesh: A Systematic Review and Meta-Analysis

  2020cites this paper
• Mechanochemical Synthesis and Physicochemical Characterization of Isoniazid and Pyrazinamide Co-crystals With Glutaric Acid

  2020cites this paper
• Detection of mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains inhibiting wild type probe hybridization in the MTBDR plus assay by DNA sequencing directly from clinical specimens

  2020cites this paper
• The most significant reasons for the failure of treatment of patients with newly diagnosed pulmonary tuberculosis and possible solutions

  2020cites this paper
• The molecular patterns of resistance to anti-tuberculosis drugs: an analysis from Istanbul, Turkey

  2020cites this paper
• Prevalence, Types and Treatment of Tuberculosis: A Review

  2020cites this paper
• PREVALENCE AND RISK FACTORS OF MULTI DRUG RESISTANT TUBERCULOSIS AMONG REFUGEES IN THE RESETTLEMENT CAMPS OF ADJUMANI, MOYO AND YUMBE DISTRICTS WEST NILE REGION.

  2020cites this paper
• Two Novel katG Mutations Conferring Isoniazid Resistance in Mycobacterium tuberculosis

  2020cites this paper
• Prevalence of drug resistance-conferring mutations associated with isoniazid and rifampicin resistant Mycobacterium tuberculosis in Ethiopia: A systematic review and meta-analysis

  2020cites this paper
• Recent updates on drug resistance in Mycobacterium tuberculosis

  2020cites this paper
• HEPATOPROTECTIVE ACTIVITY OF CAULIFLOWER LEAF EXTRACT AGAINST ISONIAZID AND RIFAMPICIN INDUCED TOXICITY IN ALBINO RATS

  2020cites this paper
• Direct-from-sputum rapid phenotypic drug susceptibility test for mycobacteria

  2020cites this paper
• Enhancing the Activity of Drugs by Conjugation to Organometallic Fragments

  2020cites this paper
• Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis.

  2020cites this paper
• Are Drug Efflux Genes Present among Mycobacterium tuberculosis Isolates from Patients in Lagos, Nigeria?

  2020cites this paper
• A stereo, regioselective synthesis and discovery of antimycobaterium tuberculosis activity of novel β-lactam grafted spirooxindolopyrrolidine hybrid heterocycles

  2020cites this paper
• Current Trends in Mycobacterium tuberculosis Pathogenesis and Drug Resistance

  2020cites this paper
• Characterization of mutations in the rpoB gene conferring rifampicin resistance in Mycobacterium tuberculosis complex isolated from lymph nodes of slaughtered cattle from South Africa

  2020cites this paper
• Gene mutations related to rifampin resistance of tuberculosis in northwest of Iran

  2020cites this paper
• Formulation and bioequivalence testing of fixed-dose combination orally disintegrating tablets for the treatment of tuberculosis in paediatric population.

  2020cites this paper
• Tuberculosis - present medication and therapeutic prospects.

  2020cites this paper
• Molecular Mechanisms of Drug Resistance in Mycobacterium tuberculosis: Role of Nanoparticles Against Multi-drug-Resistant Tuberculosis (MDR-TB)

  2020cites this paper
• Frequency and Patterns of First- and Second-Line Drug Resistance-Conferring Mutations of Mycobacterium tuberculosis Isolated from Pulmonary Tuberculosis Patients in a Cross-Sectional Study in Tigray Region, Ethiopia.

  2020cites this paper
• Comparison of Quantamatrix Multiplexed Assay Platform and GenoType MTBDR Assay Using Smear-Positive Sputum Specimens From Patients With Multidrug- Resistant/Extensively Drug-Resistant Tuberculosis in South Korea

  2019cites this paper
• New potential drug leads against MDR-MTB: A short review.

  2019cites this paper
• Potent cationic antimicrobial peptides against Mycobacterium tuberculosis in vitro.

  2019cites this paper
• How Can the Tuberculosis Laboratory Aid in the Patient-Centered Diagnosis and Management of Tuberculosis?

  2019cites this paper
• Rifampin resistance-associated mutations in the RIF resistance-determining region (RRDR) of the rpoB gene of Mycobacterium tuberculosis clinical isolates in Shanghai, China

  2019cites this paper
• Uncovering the Resistance Mechanism of Mycobacterium tuberculosis to Rifampicin Due to RNA Polymerase H451D/Y/R Mutations From Computational Perspective

  2019cites this paper
• Potential impact of efflux pump genes in mediating rifampicin resistance in clinical isolates of Mycobacterium tuberculosis from India

  2019cites this paper
• Hydrazone, benzohydrazones and isoniazid-acylhydrazones as potential antituberculosis agents.

  2019cites this paper
• The Challenge of Drug-Resistant Tuberculosis: An Update

  2019cites this paper
• Synthesis and antitubercular activity of triazole-linked 1,4-benzoquinone derivatives

  2019cites this paper
• FOR DOCTORAL DEGREE ( Ph . D . ) By SSV

  2019cites this paper